ImmunityBio (IBRX) announced the Michael E. DeBakey Department of Veterans Affairs Medical Center in Houston has become one of the first VA hospitals in the U.S. to provide treatment with ANKTIVA. ANKTIVA, in combination with BCG, is approved by the FDA for patients with BCG-unresponsive non-muscle invasive bladder cancer.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IBRX:
- ImmunityBio’s Shareholder Settlement Gains Preliminary Approval
- ImmunityBio’s ANKTIVA: Expanding Oncology Potential and Market Growth Drive Buy Rating
- ImmunityBio Reports Revenue Growth Amidst Continued Investments
- ImmunityBio’s Innovative Approach to Glioblastoma: A Promising Clinical Update
- ImmunityBio’s Innovative Immunotherapy Trial: A Potential Game-Changer in Cancer Treatment